Skip to main content


Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

Fig. 1

Patient reported neurotoxicity and global quality of life in the clarithromycin and the placebo group. In the FACT/GOG-Ntx score positive values indicate worsening of neurotoxicity and negative values indicate improvement of neurotoxicity. In the Global Quality of Life Scale (GQOL) positive values indicate improvement in quality of life and negative values indicate worsening of quality of life

Back to article page